BACKGROUND: Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased mortality. Multiple transfusions of blood and blood-related products are a potential source. AIMS: This study aims to assess the incidence of hepatitis B surface antigen (HBsAg) seroconversion in cancer patients receiving transfusion of blood or blood-related products and identify possible reasons for infection in these patients. MATERIAL AND METHODS: Patients of cancer receiving blood products, who were HBsAg-, anti-hepatitis B core (HBc)-, and HBV DNA-negative prior to transfusion, were tested for HBsAg by ELISA at 6, 12, and 24 weeks after the last transfusion. Blood donors were screened for HBsAg by ELISA. RESULTS: Twenty of 3,600 (0.56 %) blood donors tested positive for HBsAg and were rejected. Nine of 150 (6 %) cancer patients became HBsAg-positive posttransfusion which included seven patients who presented with acute hepatitis B and other two patients who remained HBsAg-positive without hepatitis. In 6/9 (66.6 %) patients, HBsAg positivity was related to blood transfusion as their corresponding blood donors on retesting the stored samples were positive for anti-HBc antibody and HBV DNA. In other three patients, the cause of their HBsAg positivity could not be ascertained. CONCLUSION: Occult HBV infection in blood donors is a potential source of posttransfusion HBV infection in recipients. Anti-HBc antibody and HBV DNA should be tested in blood donors especially when blood is given to cancer patients receiving chemotherapy.
BACKGROUND: Prevalence of hepatitis B virus (HBV) infection is increased in patients of cancer with increased mortality. Multiple transfusions of blood and blood-related products are a potential source. AIMS: This study aims to assess the incidence of hepatitis B surface antigen (HBsAg) seroconversion in cancerpatients receiving transfusion of blood or blood-related products and identify possible reasons for infection in these patients. MATERIAL AND METHODS:Patients of cancer receiving blood products, who were HBsAg-, anti-hepatitis B core (HBc)-, and HBV DNA-negative prior to transfusion, were tested for HBsAg by ELISA at 6, 12, and 24 weeks after the last transfusion. Blood donors were screened for HBsAg by ELISA. RESULTS: Twenty of 3,600 (0.56 %) blood donors tested positive for HBsAg and were rejected. Nine of 150 (6 %) cancerpatients became HBsAg-positive posttransfusion which included seven patients who presented with acute hepatitis B and other two patients who remained HBsAg-positive without hepatitis. In 6/9 (66.6 %) patients, HBsAg positivity was related to blood transfusion as their corresponding blood donors on retesting the stored samples were positive for anti-HBc antibody and HBV DNA. In other three patients, the cause of their HBsAg positivity could not be ascertained. CONCLUSION:Occult HBV infection in blood donors is a potential source of posttransfusion HBV infection in recipients. Anti-HBc antibody and HBV DNA should be tested in blood donors especially when blood is given to cancerpatients receiving chemotherapy.
Authors: Seong Man Kim; Ki Sung Lee; Chi Jun Park; Ja Young Lee; Kyung Ho Kim; Joon Yong Park; Jin Heon Lee; Hak Yang Kim; Jae Young Yoo; Myoung Kuk Jang Journal: J Infect Date: 2006-03-27 Impact factor: 6.072
Authors: W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson Journal: J Med Virol Date: 2000-11 Impact factor: 2.327
Authors: Chee-kin Hui; Jian Sun; Wing-yan Au; Albert K W Lie; Yui-hung Yueng; Hai-ying Zhang; Nikki P Lee; Jin-ling Hou; Raymond Liang; George K K Lau Journal: J Hepatol Date: 2005-03-31 Impact factor: 25.083
Authors: Mutiat K Ogunfemi; Hannah O Olawumi; Abdulfatai B Olokoba; Modu B Kagu; Sikiru A Biliaminu; Kabir A Durowade; Idayat A Durotoye; Akeem O Shittu Journal: Malawi Med J Date: 2017-03 Impact factor: 0.875
Authors: Manzoor A Wani; Jaswinder S Sodhi; Ghulam N Yatoo; Altaf Shah; Sajad Geelani; Showkat A Zargar; Ghulam M Gulzar; Mushtaq Khan; Sheikh A Aziz Journal: J Clin Exp Hepatol Date: 2020-07-08